drugset / Trial / NCT04386304
Safety and Biomarker Response to (+)-Epicatechin in Becker Muscular Dystrophy
NaSequentialOpen-labelTreatment
Summary
This is a Phase 1, open-label, dose escalation study aimed at evaluating the safety, early efficacy and potential biomarkers of (+)-epicatechin in patients with Becker or Becker-like Muscular Dystrophy (BMD).
Timeline
- Start
- 2020-07-13
- Primary completion
- 2022-03-01
- Completion
- 2022-03-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | (-)-Epicatechin | Unknown | 75 mg | Oral |
| Subject | (-)-Epicatechin | Unknown | 150 mg | Oral |
| Subject | (-)-Epicatechin | Unknown | 225 mg | Oral |